In the present study, patients with ALT ≥ 2 × ULN who received treatment had a significantly lower incidence of HCC compared to those who were not treated, after adjustment for clinical and viral risk factors with REACH-B score (P = 0.0291). This evidence concerns the gene GPT and hepatocellular carcinoma.